Bristol-Myers Squibb Company (BMY) Q1 2023 Earnings Results

Bristol Myers Squibb Beats on EPS, Stock Down 0.6%

Bristol Myers Squibb's earnings report showed a positive surprise in EPS, which reflects better-than-expected performance in that area. However, the stock reacted negatively, declining by 0.6%. This may indicate investor concerns about other aspects of the business, particularly since no revenue figures or guidance were provided.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$2.05	N/A	+3.33%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding the company's future. They emphasized their focus on pipeline advancements despite current market challenges.

Management highlighted ongoing commitment to innovation and pipeline development.

They acknowledged challenges in the market but expressed confidence in long-term growth.

Bristol Myers Squibb Beats on EPS, Stock Down 0.6%

Key numbers

Management commentary

Bristol-Myers Squibb Company

More earnings this week

Bristol Myers Squibb Beats on EPS, Stock Down 0.6%

Key numbers

Management commentary